Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

CSL stock

CSL.AX
AU000000CSL8
890952

Price

0
Today +/-
-0
Today %
-0 %

CSL stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the CSL stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the CSL stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the CSL stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze CSL's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

CSL Stock Price History

DateCSL Price
2/10/20250 undefined
2/7/2025169.47 undefined
2/6/2025171.27 undefined
2/5/2025169.70 undefined
2/4/2025171.44 undefined
2/3/2025171.78 undefined
1/31/2025174.78 undefined
1/30/2025173.75 undefined
1/29/2025172.70 undefined
1/28/2025170.29 undefined
1/24/2025171.31 undefined
1/23/2025169.55 undefined
1/22/2025169.85 undefined
1/21/2025171.73 undefined
1/20/2025171.79 undefined
1/17/2025170.32 undefined
1/16/2025171.12 undefined
1/15/2025172.05 undefined
1/14/2025173.01 undefined
1/13/2025172.90 undefined

CSL Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into CSL, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by CSL from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects CSL’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of CSL. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into CSL’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing CSL’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on CSL’s growth potential.

CSL Revenue, EBIT and net profit per share

DateCSL RevenueCSL EBITCSL Net Income
2030e23.17 B undefined7.67 B undefined5.64 B undefined
2029e21.95 B undefined7.12 B undefined5.27 B undefined
2028e19.56 B undefined6.48 B undefined4.74 B undefined
2027e18.16 B undefined5.88 B undefined4.34 B undefined
2026e16.98 B undefined5.27 B undefined3.8 B undefined
2025e15.85 B undefined4.61 B undefined3.28 B undefined
202414.8 B undefined3.81 B undefined2.64 B undefined
202313.31 B undefined3.25 B undefined2.19 B undefined
202210.56 B undefined2.93 B undefined2.25 B undefined
202110.31 B undefined3.13 B undefined2.38 B undefined
20209.15 B undefined2.72 B undefined2.1 B undefined
20198.54 B undefined2.5 B undefined1.92 B undefined
20187.92 B undefined2.38 B undefined1.73 B undefined
20176.92 B undefined1.77 B undefined1.34 B undefined
20166.12 B undefined1.44 B undefined1.24 B undefined
20155.63 B undefined1.77 B undefined1.38 B undefined
20145.52 B undefined1.66 B undefined1.31 B undefined
20135.13 B undefined1.52 B undefined1.22 B undefined
20124.77 B undefined1.3 B undefined1.01 B undefined
20114.26 B undefined1.2 B undefined936.5 M undefined
20104.06 B undefined1.23 B undefined926.7 M undefined
20093.69 B undefined1.05 B undefined842.2 M undefined
20083.4 B undefined896.3 M undefined627.9 M undefined
20072.6 B undefined643 M undefined423.3 M undefined
20062.17 B undefined158.4 M undefined87.7 M undefined
20052.45 B undefined648.4 M undefined411 M undefined

CSL Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (B)NET INCOME (B)NET INCOME GROWTH (%)DIV. ()DIV. GROWTH (%)SHARES (M)DOCUMENTS
19971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025e2026e2027e2028e2029e2030e
0.250.250.270.320.460.710.761.312.452.172.63.43.694.064.264.775.135.525.636.126.927.928.549.1510.3110.5613.3114.815.8516.9818.1619.5621.9523.17
--7.2618.8044.9454.158.2270.8187.43-11.2819.8230.588.699.925.0811.857.597.701.888.6513.2014.357.877.1712.682.4326.0311.197.107.146.957.6712.265.52
3,093.153,093.152,883.8351.2744.5439.6637.5741.6948.1241.3847.5449.1652.2052.5950.7350.3953.3852.8653.7050.0751.9555.3855.9557.1156.6754.2851.2851.8348.3945.1742.2339.2334.9433.11
0000.160.20.280.290.541.180.91.241.671.932.132.162.42.742.923.023.063.64.384.785.235.845.736.837.67000000
0.030.030.030.030.040.060.040.160.410.090.420.630.840.930.941.011.221.311.381.241.341.731.922.12.382.252.192.643.283.84.344.745.275.64
-11.11-3.3317.2423.5352.38-35.94280.49163.46-78.83386.2148.2334.299.981.088.2320.047.485.51-9.937.6529.2411.009.5912.99-5.09-2.6620.4224.1515.8814.299.1411.186.96
----------------------------------
----------------------------------
399.1400.9401.9408454.5479478.8536.6590.8571.3551.4553.3597.7568.6541.8520.3500.3485.6473.17463.12456.37453.88454.03455.61456.2468.75483.89485.2000000
----------------------------------
Details

Keystats

ⓘ

Revenue and Growth

The CSL Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the CSL is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (B)RECEIVABLES (B)OTHER REC. (M)INVENTORIES (B)OTHER CURRENT LIAB. (M)CURRENT ASSETS (B)TANGIBLE ASSETS (B)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (B)GOODWILL (B)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (B)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (B)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (B)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (B)LIABILITIES (M)PROVISIONS (B)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (B)SHORT-TERM REC. (B)LONG-T. LIAB. (B)DEFERRED TAXES (B)OTHER LIAB. (B)LONG-T. LIABILITIES (B)DEBT (B)TOTAL CAPITAL (B)
1997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024
                                                       
0.030.030.030.250.060.060.060.080.550.570.410.672.040.840.531.180.760.610.560.560.850.820.661.21.8110.441.561.66
0.020.020.030.040.080.10.110.350.380.390.450.570.610.670.760.680.740.830.890.930.961.091.441.291.211.151.62.27
7553599272934528391467284848787.9116.6157.5278.7287.4306.3440362.2336495
0.050.050.070.070.140.250.330.940.720.720.961.151.231.221.561.51.641.651.762.152.582.693.043.513.784.335.475.96
0111434221721232722223229363945.264.563.1112.5116.8145.7147.5174300380
0.120.110.130.360.290.420.51.421.71.731.892.53.992.82.963.483.263.213.343.824.64.995.546.457.3916.469.2610.77
0.220.180.210.190.260.320.360.620.590.610.730.940.971.011.291.391.591.831.842.392.943.554.486.317.548.319.359.66
302125431261541287421110.52.93.96.29.914.221.5402.9173163
002100000987831119811.215.616.515.321.614.36.612.896158
000000.030.050.050.070.060.230.230.170.20.220.190.170.190.220.270.370.70.781.11.481.458.378.27
00000.340.520.550.550.50.550.560.640.610.610.760.690.690.730.710.670.691.11.11.191.191.198.088.08
1411139811236285146139174183168193200264306282394502.1405.4380.2544.4533.4522.9908929
0.270.220.250.20.620.890.991.291.251.371.6821.951.992.472.482.723.073.063.744.525.786.779.1710.7711.8926.9827.25
0.380.330.380.560.911.31.492.712.953.113.564.55.944.85.435.955.986.286.47.569.1210.7712.3115.6218.1628.3536.2338.02
                                                       
0.10.080.160.350.310.520.631.050.930.740.870.992.230.960.2700000000004.990.520.56
756300000000000000000000000000
0.10.10.120.120.140.20.230.40.650.741.061.862.222.864.194.544.535.366.156.757.578.699.8611.0812.6814.0415.2516.81
00000000000-164-41-274-558-1,033-1,527-2,198-3,405-4,184.5-4,408.3-4,605.4-4,608.6-4,553.4-4,298.1-4,451.322-4
0000000000000000000000000000
0.270.240.280.470.450.720.861.451.581.481.932.694.413.543.913.513.013.162.752.573.164.085.256.538.3814.5815.7917.36
16141820395975162112289373426535408529541624601678.4972.6399417.4422.6458.3523591.8820867
00000000000000000.020.120.10.120.860.961.121.221.731.882.372.69
353346447412289316284199183252185231243247253122149.6217236.4315.9229.5257.7378.4141.3360448
1011490334565613221.31.31.52181.953.178.71023914
00000.030.0400.010.010.270.120.120.260.020.240.170000.060.120.220.240.150.44.391.020.93
0.050.050.070.070.140.230.160.490.410.770.680.80.990.661.020.960.910.840.941.371.621.912.192.143.17.114.614.95
0.030.010.0100.290.310.390.470.650.440.720.790.310.370.21.131.671.892.283.083.854.164.245.795.335.1611.1711.24
0.010.010.010.010.010.010.030.060.080.050.070.090.090.10.130.110.120.130.140.120.140.190.170.390.460.671.461.51
0.020.020.020.020.020.030.050.240.240.380.170.130.150.130.180.250.270.260.30.420.350.430.460.770.880.831.160.92
0.060.040.030.030.310.360.470.770.970.870.961.010.550.60.511.492.062.272.723.624.344.784.876.956.676.6613.813.67
0.110.080.10.090.460.590.631.261.371.631.641.811.541.261.532.452.973.123.6555.966.697.069.099.7813.7718.4118.62
0.390.320.380.570.911.31.52.712.953.113.564.55.944.85.435.955.986.286.47.569.1210.7712.3115.6218.1628.3534.1935.98
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of CSL provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand CSL's financial health and stability.

Assets

CSL's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that CSL must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of CSL after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into CSL's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (B)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (B)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (B)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (B)NET CHANGE IN EQUITY (B)CASH FLOW FROM FINANCING ACTIVITIES (B)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (B)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
000000000000000000000002.572.962.782.66
00000000000000000000000419589668831
000000000000000000000000000
00000000.010.010.020.030.030.050.030.030.040.030.021.361.181.251.91.64-0.93-0.48-1.47-1.57
00000000000000000000000423544647675
-2000-6-18-26-17-23-24-29-40-45-17-13-35-49-5000000142160172374
-8-10-14-17-16-11-17-32-32-95-137-212-216-158-284-252-298-34900000355494457563
0.050.050.050.030.070.070.070.150.430.390.380.640.751.0311.21.311.361.361.181.251.91.642.493.622.632.6
-13-14-24-23-32-43-64-62-85-97-223-218-233-260-209-320-450-401-413-565-860-992-1,284-1,367-1,667-1,247-1,692
-12-18-24-3-519-212-91-515163-117-655-213-330-257-206-319-449-401-413-810-862-1,534-1,287-1,366-1,673-1,636-11,843
0-4019-486-168-27-453249-20-4325-96221000-244-2-541-20-6-388-10,151
000000000000000000000000000
-0-0.02-0-00.3-0.020.050.020.15-00.18-0.03-0.29-0.190.030.850.390.20.490.850.80.420.290.2-0.53.721.66
0000.2200.1700.39-0.23-0.170.020.011.33-1.5-0.87-0.64-1.11-0.81-0.78-0.63-0.3-0.120.030.040.064.990.03
-0.01-0.03-0.020.20.290.130.020.39-0.13-0.270.08-0.220.77-2.07-1.27-0.22-1.22-1.14-0.83-0.36-0.1-0.37-0.49-0.64-1.47.680.46
0000000-70000-25000000000-40-32-154
-13-14-15-18-19-24-31-25-47-92-127-203-234-378-429-435-499-521-535-579-601-672-806-883-958-1,038-1,085
0.070.050.060.28-0.080.090.110.210.930.510.31.062.31-0.170.762.141.221.59-0.0500.29-0.03-0.150.490.588.6-8.83
32.331.220.910.636.624.72.884.8341.3292.5153.9421.1519.5767.7794.9875.5861.6958.8949.8612.9386909.5359.61,120.71,954.81,381909
000000000000000000000000000

CSL stock margins

The CSL margin analysis displays the gross margin, EBIT margin, as well as the profit margin of CSL. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for CSL.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the CSL's sales revenue. A higher gross margin percentage indicates that the CSL retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the CSL's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the CSL's total revenue generated. When comparing the revenue margin year over year, investors can gauge the CSL's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the CSL. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the CSL's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

CSL Margin History

CSL Gross marginCSL Profit marginCSL EBIT marginCSL Profit margin
2030e51.83 %33.1 %24.34 %
2029e51.83 %32.41 %24.01 %
2028e51.83 %33.12 %24.25 %
2027e51.83 %32.38 %23.92 %
2026e51.83 %31.02 %22.38 %
2025e51.83 %29.06 %20.69 %
202451.83 %25.76 %17.85 %
202351.28 %24.44 %16.48 %
202254.27 %27.72 %21.35 %
202156.68 %30.36 %23.04 %
202057.11 %29.69 %22.98 %
201955.95 %29.33 %22.47 %
201855.38 %30.07 %21.84 %
201751.94 %25.55 %19.32 %
201650.08 %23.51 %20.32 %
201553.7 %31.51 %24.5 %
201452.86 %30 %23.66 %
201353.38 %29.54 %23.71 %
201250.39 %27.16 %21.25 %
201150.74 %28.27 %21.97 %
201052.59 %30.32 %22.84 %
200952.21 %28.51 %22.82 %
200849.17 %26.4 %18.49 %
200747.56 %24.73 %16.28 %
200641.39 %7.3 %4.04 %
200548.15 %26.51 %16.8 %

CSL Stock Sales Revenue, EBIT, Earnings per Share

The CSL earnings per share therefore indicates how much revenue CSL has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue CSL earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates CSL's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of CSL’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating CSL's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

CSL Revenue, EBIT and net profit per share

DateCSL Sales per ShareCSL EBIT per shareCSL Earnings per Share
2030e47.84 undefined0 undefined11.65 undefined
2029e45.34 undefined0 undefined10.89 undefined
2028e40.39 undefined0 undefined9.79 undefined
2027e37.51 undefined0 undefined8.97 undefined
2026e35.07 undefined0 undefined7.85 undefined
2025e32.74 undefined0 undefined6.77 undefined
202430.5 undefined7.86 undefined5.45 undefined
202327.51 undefined6.72 undefined4.53 undefined
202222.53 undefined6.25 undefined4.81 undefined
202122.6 undefined6.86 undefined5.21 undefined
202020.08 undefined5.96 undefined4.61 undefined
201918.81 undefined5.52 undefined4.23 undefined
201817.44 undefined5.24 undefined3.81 undefined
201715.17 undefined3.88 undefined2.93 undefined
201613.2 undefined3.1 undefined2.68 undefined
201511.89 undefined3.75 undefined2.91 undefined
201411.38 undefined3.41 undefined2.69 undefined
201310.25 undefined3.03 undefined2.43 undefined
20129.16 undefined2.49 undefined1.95 undefined
20117.87 undefined2.22 undefined1.73 undefined
20107.13 undefined2.16 undefined1.63 undefined
20096.17 undefined1.76 undefined1.41 undefined
20086.14 undefined1.62 undefined1.13 undefined
20074.72 undefined1.17 undefined0.77 undefined
20063.8 undefined0.28 undefined0.15 undefined
20054.14 undefined1.1 undefined0.7 undefined

CSL business model

CSL Ltd is a global leading company in the field of biological medicine, manufacturing a wide range of products used in the therapy of diseases. The company is based in Melbourne, Australia, and is one of the largest biotech companies in the country. CSL was founded in 1916 by Australian researcher Frank Macfarlane Burnet. Originally named Commonwealth Serum Laboratories, the company focused on the research and production of vaccines. CSL was then privatized in 1994 and changed its name to CSL Ltd. CSL's business model is based on the production of protein products and plasma derivatives used in immunotherapy, hematology, and transplantation medicine. The company specializes in the production and marketing of products in three main areas: plasma products, vaccines, and animal health. CSL's plasma division includes a variety of products, including intravenous immunoglobulins (IVIG), platelets, and alpha-1 antitrypsin. The company operates a number of plasma centers in the US and Europe to collect raw materials for these products. In the vaccine sector, CSL is primarily involved in the manufacture of influenza vaccines and also offers a range of other vaccines, including vaccines against snake bites and encephalitis. In the field of animal health, CSL produces animal vaccines to prevent viral infections in livestock such as pigs, poultry, and cattle. CSL is committed to research and development to develop new products and improve existing ones. The company has a long history in the research and development of vaccines and immunotherapies and has established a strong presence in this field. The company employs over 27,000 people in 35 countries worldwide and operates production facilities in Australia, the US, Europe, and Asia. CSL's headquarters are located in Parkville, a suburb of Melbourne, Australia. CSL has an impressive track record in terms of growth and profitability and is a stable market leader in its field. The company has achieved solid growth rates in recent years and generated a revenue of $8.5 billion in 2019. CSL is a key player in the global healthcare industry and has established a reputation as a reliable supplier of medical products and services. The company is committed to developing innovative solutions to advance medical progress and make a positive contribution to human health. CSL is one of the most popular companies on Eulerpool.com.

CSL SWOT Analysis

Strengths

CSL Ltd has a strong portfolio of life-saving products, including vaccines, gene therapies, and plasma-derived therapies. This diverse product range helps to mitigate risks and ensures a consistent revenue stream.

The company has a major competitive advantage through its strong research and development capabilities. It invests heavily in innovation and clinical trials, resulting in a continuous pipeline of new products and treatments.

Weaknesses

One of CSL Ltd's weaknesses lies in its geographical concentration of operations. With the majority of its manufacturing facilities located in Australia, the company is exposed to risks associated with regulatory changes, natural disasters, and disruptions in the supply chain.

Additionally, CSL Ltd heavily relies on plasma for its products. Any significant disruption in the plasma supply chain could impact production and lead to potential shortages.

Opportunities

The increasing demand for healthcare products and services globally provides CSL Ltd with significant growth opportunities. Expanding into emerging markets with a high demand for quality healthcare can help the company increase its market share and revenue.

The advancements in gene therapies and biotechnology open doors for CSL Ltd to develop new and innovative treatments. Partnering with academic institutions and biotechnology companies can enable the company to stay at the forefront of cutting-edge research.

Threats

CSL Ltd faces the threat of increasing competition from both established pharmaceutical companies and emerging biotech startups. This could potentially impact market share and profit margins.

The changing regulatory landscape, especially in the healthcare industry, also poses a threat to CSL Ltd. Compliance with evolving regulations and the possibility of stricter regulations can increase costs and limit operational flexibility.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

CSL Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

CSL historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

CSL shares outstanding

The number of shares was CSL in 2024 — This indicates how many shares 485.199 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue CSL earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates CSL's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of CSL’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating CSL's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

CSL stock splits

In CSL's history, there have been no stock splits.

CSL dividend history and estimates

In 2024, CSL paid a dividend amounting to 3.97 USD. Dividend means that CSL distributes a portion of its profits to its owners.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details

Dividend

ⓘ

Dividend Overview

The dividend per year chart for CSL provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.

Interpretation and Use

A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify CSL’s potential for long-term investment and income generation through dividends.

Investment Strategy

Incorporate the dividend data in evaluating CSL's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.

CSL Dividend History

DateCSL Dividend
2030e4.2 undefined
2029e4.2 undefined
2028e4.2 undefined
2027e4.2 undefined
2026e4.2 undefined
2025e4.19 undefined
20243.97 undefined
20233.72 undefined
20223.26 undefined
20213.01 undefined
20202.94 undefined
20192.66 undefined
20182.28 undefined
20171.75 undefined
20161.7 undefined
20151.64 undefined
20141.24 undefined
20131.06 undefined
20120.83 undefined
20110.81 undefined
20100.82 undefined
20090.7 undefined
20080.56 undefined
20070.39 undefined
20060.23 undefined
20050.12 undefined

CSL dividend payout ratio

In 2024, CSL had a payout ratio of 62.84%. The payout ratio indicates the percentage of the company's profits that CSL distributes as dividends.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Payout ratio
Details

Payout ratio

ⓘ

What is Yearly Payout Ratio?

The yearly payout ratio for CSL represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.

How to Interpret the Data

A lower payout ratio for CSL could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.

Using the Data for Investments

Evaluate CSL's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.

CSL Payout Ratio History

DateCSL Payout ratio
2030e63.72 %
2029e63.66 %
2028e63.88 %
2027e63.62 %
2026e63.48 %
2025e64.54 %
202462.84 %
202363.06 %
202267.7 %
202157.76 %
202063.73 %
201962.89 %
201859.94 %
201759.82 %
201663.42 %
201556.4 %
201446 %
201343.47 %
201242.56 %
201146.73 %
201050.38 %
200949.65 %
200849.43 %
200750.12 %
2006151.1 %
200516.69 %
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for CSL.

CSL latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/20241.71 1.83  (6.84 %)2024 Q4
12/31/20234.3 4.16  (-3.27 %)2024 Q2
6/30/20233.31 1.17  (-64.68 %)2023 Q4
12/31/20223.66 3.36  (-8.29 %)2023 Q2
6/30/20221.1 0.96  (-13.08 %)2022 Q4
12/31/20213.6 3.84  (6.72 %)2022 Q2
6/30/20211.06 1.24  (17.3 %)2021 Q4
12/31/20203.14 3.97  (26.25 %)2021 Q2
6/30/20201.95 1.88  (-4.06 %)2020 Q4
12/31/20192.87 2.74  (-4.48 %)2020 Q2
1
2
3

Eulerpool ESG Scorecard© for the CSL stock

Eulerpool World ESG Rating (EESG©)

83/ 100

🌱 Environment

67

👫 Social

99

🏛️ Governance

83

Environment

Scope 1 - Direct Emissions
114,240
Scope 2 - Indirect emissions from purchased energy
221,760
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
336,000
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees59
Percentage of women in management
Percentage of Asian employees5
Share of Asian management
Percentage of Hispanic/Latino employees17
Hispano/Latino Management share
Percentage of Black employees28
Black Management Share
Percentage of white employees45
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

CSL shareholders

%
Name
Stocks
Change
Date
4.97984 % The Vanguard Group, Inc.24,112,87506/30/2024
3.99503 % State Street Global Advisors Australia Ltd.19,344,32406/30/2024
2.91281 % BlackRock Institutional Trust Company, N.A.14,104,12606/30/2024
1.69992 % Norges Bank Investment Management (NBIM)8,231,175428,6106/30/2024
1.57634 % Vanguard Investments Australia Ltd.7,632,81214,6389/30/2024
1.26557 % State Street Global Advisors (US)6,128,03106/30/2024
1.07524 % Colonial First State Investments Limited5,206,440471,8597/31/2024
0.95547 % BlackRock Investment Management (Australia) Ltd.4,626,48406/30/2024
0.85192 % Geode Capital Management, L.L.C.4,125,0972439/30/2024
0.72102 % Commonwealth Superannuation Corporation3,491,236213,0197/31/2024
1
2
3
4
5
...
10

CSL Executives and Management Board

Mr. Paul Mckenzie

(57)
CSL Chief Executive Officer, Managing Director, Executive Director (since 2019)
Compensation 2.75 M

Mr. William Campbell

(64)
CSL Executive Vice President, Chief Commercial Officer
Compensation 2.55 M

Mr. Greg Boss

(61)
CSL Executive Vice President, Legal and CSL Group General Counsel
Compensation 2.5 M

Dr. William Mezzanotte

(64)
CSL Executive Vice President, Head Research & Development and Chief Medical Officer
Compensation 2.16 M

Ms. Joy Linton

(57)
CSL Chief Financial Officer
Compensation 2.05 M
1
2
3
4
...
5

CSL Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
uniQure Stock
uniQure
SupplierCustomer0,66-0,15-0,340,700,820,42
Ligand Pharmaceuticals Stock
Ligand Pharmaceuticals
SupplierCustomer0,44-0,15-0,500,570,65-0,06
DCC Stock
DCC
SupplierCustomer0,430,180,71-0,190,11-0,14
Kamada Stock
Kamada
SupplierCustomer0,40-0,27-0,630,400,030,07
ALK-Abello B Stock
ALK-Abello B
SupplierCustomer0,30-0,390,190,670,510,12
Valneva Stock
Valneva
SupplierCustomer0,29-0,20-0,460,630,340,09
Aslan Pharmaceuticals ADR Stock
Aslan Pharmaceuticals ADR
SupplierCustomer0,27-0,40-0,620,500,580,05
Mustang Bio Stock
Mustang Bio
SupplierCustomer0,24-0,05-0,290,740,730,25
Johnson & Johnson Stock
Johnson & Johnson
SupplierCustomer0,230,020,71-0,29-0,28-0,23
AstraZeneca Stock
AstraZeneca
SupplierCustomer0,230,020,65-0,27-0,45-0,01
1
2

Most common questions regarding CSL

What values and corporate philosophy does CSL represent?

CSL Ltd represents strong values and a dedicated corporate philosophy. As a global biotechnology company, CSL is committed to enhancing the health and well-being of people worldwide. The company strives for excellence in its operations, focusing on innovation, quality, and patient-centric outcomes. CSL upholds integrity, ethics, and transparency in all aspects of its business, fostering trust with stakeholders. With a mission to save lives and improve patient outcomes, CSL maintains a customer-driven approach, continuously working towards breakthroughs in medical research and development. Through its commitment to these values and corporate philosophy, CSL Ltd demonstrates its dedication to making a positive impact on global healthcare.

In which countries and regions is CSL primarily present?

CSL Ltd is primarily present in various countries and regions across the globe. These include Australia, the company's home country where it is headquartered, North America, Europe, and Asia-Pacific. With a strong global presence, CSL Ltd has established itself as a leading biotechnology company, providing innovative and life-saving solutions in the areas of vaccines, plasma therapies, and recombinant products. As a multinational corporation, CSL Ltd has successfully expanded its operations and collaborations internationally, further strengthening its position in the global market.

What significant milestones has the company CSL achieved?

CSL Ltd, a renowned Australian biotechnology company, has achieved numerous significant milestones throughout its history. Notably, CSL Ltd successfully developed and marketed first-of-its-kind blood plasma products and vaccines. They introduced the world's first recombinant product derived from human genes, being pivotal in the treatment of hemophilia. CSL Ltd has also made groundbreaking advancements in the field of immunoglobulins, leading to innovative therapies. Furthermore, the company expanded its global presence and became a major player in the biopharmaceutical industry. With its dedication to research, development, and revolutionizing healthcare, CSL Ltd continues to make remarkable contributions to the medical field.

What is the history and background of the company CSL?

CSL Ltd, also known as CSL Limited, is a global biotechnology company headquartered in Australia. Established in 1916, CSL has a rich history of over a century. Originally known as the Commonwealth Serum Laboratories, it transitioned into a private company in 1994. CSL specializes in the research, development, manufacturing, and marketing of innovative biotherapies and vaccines to combat serious medical conditions. With a strong commitment to improving public health, CSL has expanded its operations globally and has become a trusted name in the biopharmaceutical industry. Today, CSL Ltd continues to make significant contributions to healthcare worldwide through its advanced technologies and dedicated team.

Who are the main competitors of CSL in the market?

The main competitors of CSL Ltd in the market are Biogen Inc., Grifols S.A., and Shire Plc.

In which industries is CSL primarily active?

CSL Ltd is primarily active in the biotechnology and pharmaceutical industries.

What is the business model of CSL?

The business model of CSL Ltd is focused on providing innovative biotherapies and pharmaceutical products to patients worldwide. With a strong commitment to research and development, CSL specializes in developing plasma-derived and recombinant therapies for various medical conditions. The company's portfolio includes immunoglobulins, vaccines, and coagulation factors, among others. CSL operates through its two main business segments, CSL Behring and Seqirus. CSL Behring focuses on developing and manufacturing therapies for rare and serious diseases, while Seqirus is dedicated to producing influenza vaccines. CSL Ltd's business model emphasizes delivering high-quality and life-saving treatments to improve the health and well-being of individuals globally.

What is the P/E ratio of CSL 2025?

The P/E ratio cannot be calculated for CSL at the moment.

What is the P/S ratio of CSL 2025?

The P/S cannot be calculated for CSL currently.

What is the Quality Investing of CSL?

The Quality Investing for CSL is 9/10.

What is the revenue of CSL 2025?

The expected CSL revenue is 15.85 B USD.

How high is the profit of CSL 2025?

The expected CSL profit is 3.28 B USD.

What is the business model of CSL

CSL is a global biotechnology company focused on the production of plasma and vaccine products. The company is divided into two divisions: CSL Behring and Seqirus. CSL Behring produces plasma derivatives used to treat life-threatening diseases and disorders such as Alpha-1 antitrypsin deficiency, bleeding disorders, and immune deficiencies. CSL Behring is the third largest producer of plasma derivatives worldwide with production facilities on five continents. Seqirus is the vaccine division of CSL and focuses on the research, development, manufacturing, and marketing of influenza vaccines. The company is the second largest producer of influenza vaccines globally and has production facilities worldwide. Additionally, CSL also produces products in the field of immunosuppression and inflammatory diseases. The company prides itself on meeting some of the highest quality standards in the industry and collaborate closely with patient organizations to promote understanding of the importance of plasma derivatives and vaccines. CSL's business model is based on the research, development, and production of biological products to treat and prevent life-threatening diseases and disorders. CSL's plasma derivatives and vaccines are often life-saving and essential for the health and lives of many people. CSL invests significantly in research and development to develop and improve new products and treatments. The company works closely with government agencies and health organizations to ensure that its products meet the highest standards and are accessible worldwide. To further strengthen its business model, CSL has developed a long-term growth strategy based on innovation, capacity expansion, and geographic expansion. The company will continue to invest in new technologies and research and development to meet the growing demand for life-saving products and treatments. In summary, CSL is a global biotechnology company focused on the production of plasma derivatives and vaccines. The company has two main divisions, CSL Behring and Seqirus, and also produces products in the field of immunosuppression and inflammatory diseases. The business model is based on research, development, and production of biological products to treat and prevent life-threatening diseases and disorders. The company invests significantly in research and development to develop and improve new products and treatments and has developed a long-term growth strategy to meet the growing demand for life-saving products and treatments.

What is the CSL dividend?

CSL pays a dividend of 3.26 USD distributed over 2 payouts per year.

How often does CSL pay dividends?

CSL pays out a dividend 2 times a year.

What is the CSL ISIN?

The ISIN of CSL is AU000000CSL8.

What is the CSL WKN?

The WKN of CSL is 890952.

What is the CSL ticker?

The ticker of CSL is CSL.AX.

How much dividend does CSL pay?

Over the past 12 months, CSL paid a dividend of 3.97 USD . This corresponds to a dividend yield of about . For the coming 12 months, CSL is expected to pay a dividend of 4.2 USD.

What is the dividend yield of CSL?

The current dividend yield of CSL is .

When does CSL pay dividends?

CSL pays a quarterly dividend. This is distributed in the months of April, October, April, October.

How secure is the dividend of CSL?

CSL paid dividends every year for the past 26 years.

What is the dividend of CSL?

For the upcoming 12 months, dividends amounting to 4.2 USD are expected. This corresponds to a dividend yield of 2.48 %.

In which sector is CSL located?

CSL is assigned to the 'Health' sector.

Wann musste ich die Aktien von CSL kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of CSL from 10/2/2024 amounting to 2.175 USD, you needed to have the stock in your portfolio before the ex-date on 9/9/2024.

When did CSL pay the last dividend?

The last dividend was paid out on 10/2/2024.

What was the dividend of CSL in the year 2024?

In the year 2024, CSL distributed 3.715 USD as dividends.

In which currency does CSL pay out the dividend?

The dividends of CSL are distributed in USD.

All fundamentals about CSL

Our stock analysis for CSL Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of CSL Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.